Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Metastatic Androgen-Independent Prostate Cancer
NCT00090545Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2004
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in prostate cancer (PCa), sponsored by National Cancer Institute. Primary endpoint: Progression Free Survival at 4 months. Started Sep 2004; status: completed.
02
Drugs
sorafenib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00090545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090545.